医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

New Frontier Health Corporation to Participate in UBS Virtual Global Healthcare Conference 2020

2020年05月18日 PM09:30
このエントリーをはてなブックマークに追加


 

BEIJING

New Frontier Health Corporation (“NFH” or “the Company”) (NYSE: NFH), operator of the premium healthcare services provider United Family Healthcare (“UFH”), today announced that its management team will participate in the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020, at 8:20 am U.S. Eastern Time.

A live webcast of management’s presentation will be available on the “Events & Presentations” section of the Company’s investor relations website at www.nfh.com.cn. A replay of the webcast will be available for 30 days.

About New Frontier Health Corporation

New Frontier Health Corporation (NYSE: NFH) is the operator of United Family Healthcare (UFH), a leading private healthcare provider offering comprehensive premium healthcare services in China through a network of private hospitals and affiliated ambulatory clinics. UFH currently has nine hospitals in operation or under construction in all four 1st tier cities and select 2nd tier cities. Additional information may be found at www.nfh.com.cn.

Source: New Frontier Health Corporation

View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005283/en/

CONTACT

Media

Harry Chang

Tel: +852-9822-1806

Email: harry@new-frontier.com

Wenjing Liu

Tel: +86-186-1151-5796

Email: liu.wenjing@ufh.com.cn

Investors

ICR, LLC

William Zima/Rose Zu

Tel: +1-203-682-8200

Email: bill.zima@icrinc.com/rose.zu@icrinc.com

同じカテゴリーの記事 

  • Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
  • 领先的合同开发和制造组织PCI Pharma Services发布首份综合ESG报告
  • EverEx Secures iF Design Award for “MORA,” a Leading Musculoskeletal Rehabilitation Solution
  • Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
  • SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC